Cargando…
Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688536/ https://www.ncbi.nlm.nih.gov/pubmed/38046899 http://dx.doi.org/10.1097/SP9.0000000000000009 |
_version_ | 1785152189746905088 |
---|---|
author | Gomez Rivas, Juan Nicoletti, Rossella Ibáñez, Laura Steinbeisser, Carl de Meulder, Bertrand Golozar, Asieh Axelsson, Susan Evans Snijder, Robert Bjartell, Anders Cornford, Philip Van Hemelrijck, Mieke Beyer, Katharina Willemse, Peter-Paul Murtola, Teemu Roobol, Monique J. Moreno-Sierra, Jesús Campi, Riccardo Gacci, Mauro Mottet, Nicolas Merseburger, Axel Ndow, James |
author_facet | Gomez Rivas, Juan Nicoletti, Rossella Ibáñez, Laura Steinbeisser, Carl de Meulder, Bertrand Golozar, Asieh Axelsson, Susan Evans Snijder, Robert Bjartell, Anders Cornford, Philip Van Hemelrijck, Mieke Beyer, Katharina Willemse, Peter-Paul Murtola, Teemu Roobol, Monique J. Moreno-Sierra, Jesús Campi, Riccardo Gacci, Mauro Mottet, Nicolas Merseburger, Axel Ndow, James |
author_sort | Gomez Rivas, Juan |
collection | PubMed |
description | Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate and prednisolone, apalutamide , enzalutamide and darolutamide (in combination with docetaxel chemotherapy) has proven that combination of treatments is more effective. Recently, intensification therapy, so-called “triplets”, have emerged in the armamentarium of mHSPC treatment. Metastatic disease is a clinical state that remains poorly understood. The optimal diagnostic and management of patients with mHSPC are changing thanks to the development of new imaging techniques and therapies. The primary objective of this study is to develop and validate a predictive model for the occurrence of symptomatic progression, initiation of new treatments and death amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission. |
format | Online Article Text |
id | pubmed-10688536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106885362023-12-01 Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program Gomez Rivas, Juan Nicoletti, Rossella Ibáñez, Laura Steinbeisser, Carl de Meulder, Bertrand Golozar, Asieh Axelsson, Susan Evans Snijder, Robert Bjartell, Anders Cornford, Philip Van Hemelrijck, Mieke Beyer, Katharina Willemse, Peter-Paul Murtola, Teemu Roobol, Monique J. Moreno-Sierra, Jesús Campi, Riccardo Gacci, Mauro Mottet, Nicolas Merseburger, Axel Ndow, James Int J Surg Protoc Protocol Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate and prednisolone, apalutamide , enzalutamide and darolutamide (in combination with docetaxel chemotherapy) has proven that combination of treatments is more effective. Recently, intensification therapy, so-called “triplets”, have emerged in the armamentarium of mHSPC treatment. Metastatic disease is a clinical state that remains poorly understood. The optimal diagnostic and management of patients with mHSPC are changing thanks to the development of new imaging techniques and therapies. The primary objective of this study is to develop and validate a predictive model for the occurrence of symptomatic progression, initiation of new treatments and death amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission. Lippincott Williams & Wilkins 2023-10-17 /pmc/articles/PMC10688536/ /pubmed/38046899 http://dx.doi.org/10.1097/SP9.0000000000000009 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Protocol Gomez Rivas, Juan Nicoletti, Rossella Ibáñez, Laura Steinbeisser, Carl de Meulder, Bertrand Golozar, Asieh Axelsson, Susan Evans Snijder, Robert Bjartell, Anders Cornford, Philip Van Hemelrijck, Mieke Beyer, Katharina Willemse, Peter-Paul Murtola, Teemu Roobol, Monique J. Moreno-Sierra, Jesús Campi, Riccardo Gacci, Mauro Mottet, Nicolas Merseburger, Axel Ndow, James Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program |
title | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program |
title_full | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program |
title_fullStr | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program |
title_full_unstemmed | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program |
title_short | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program |
title_sort | research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: pioneer imi’s “big data for better outcomes” program |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688536/ https://www.ncbi.nlm.nih.gov/pubmed/38046899 http://dx.doi.org/10.1097/SP9.0000000000000009 |
work_keys_str_mv | AT gomezrivasjuan researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT nicolettirossella researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT ibanezlaura researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT steinbeissercarl researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT demeulderbertrand researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT golozarasieh researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT axelssonsusanevans researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT snijderrobert researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT bjartellanders researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT cornfordphilip researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT vanhemelrijckmieke researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT beyerkatharina researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT willemsepeterpaul researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT murtolateemu researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT roobolmoniquej researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT morenosierrajesus researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT campiriccardo researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT gaccimauro researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT mottetnicolas researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT merseburgeraxel researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram AT ndowjames researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram |